Response to: ‘Correspondence on ‘Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial’’ by Wanget al
Open Access
- 27 January 2021
- journal article
- letter
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 82 (3), e68
- https://doi.org/10.1136/annrheumdis-2021-219882
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Interleukin 6 receptor inhibition in primary Sjogren syndrome: a multicentre double-blind randomised placebo-controlled trialAnnals Of The Rheumatic Diseases, 2021
- Efficacy and safety of abatacept in active primary Sjogren's syndrome: results of a phase III, randomised, placebo-controlled trialAnnals Of The Rheumatic Diseases, 2021
- Correspondence on ‘Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial’Annals Of The Rheumatic Diseases, 2021
- A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren’s syndromeRheumatology, 2020
- Advances in treatments for Sjogren's syndrome: CmseMark the glass is half fullThe Lancet Rheumatology, 2020
- Leflunomide–hydroxychloroquine combination therapy in patients with primary Sjögren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trialThe Lancet Rheumatology, 2020
- Abatacept treatment for patients with early active primary Sjögren's syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study)The Lancet Rheumatology, 2020
- Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept studyThe Lancet Rheumatology, 2020
- Treatment of primary Sjögren’s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicityAnnals Of The Rheumatic Diseases, 2019